Laurus Labs Limited
Laurus Labs Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹2,206 cr of revenue in its latest quarter (Q2 FY27) and kept 20.0% of sales as profit. It is the 4th largest of 9 Pharmaceuticals companies we track, by market value.
“Board Experience Pharma Industry Experience of Directors in Board 20% Pharma experience 90% Our Board of Directors plays a central role in upholding strong governance, ensuring No pharma experience 10% transparency, accountability and ethical oversight across the organisation. It 10% guides strategic direction while safeguarding stakeholder interests and enabling 70% sustainable growth.”
Healthier than 56% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 37–153 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 69
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold
What if I invest in LAURUSLABS?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 15%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-11-04.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹2,206 cr |
| Other Income | ₹13 cr |
| Total Income | ₹2,219 cr |
| Cost of Materials | ₹901 cr |
| Purchases of Stock-in-Trade | ₹45 cr |
| Inventory Change (±) | ₹-130 cr |
| Employee Benefit Expense | ₹266 cr |
| Finance Costs | ₹44 cr |
| Depreciation & Amortisation | ₹127 cr |
| Other Expenses | ₹374 cr |
| Total Expenses | ₹1,628 cr |
| Profit before Tax | ₹592 cr |
| Tax Expense | ₹155 cr |
| Share of JV / Associates | ₹-55 L |
| Net Profit | ₹436 cr |
| Net margin on total income | 19.7% |
| Metric | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|
| Revenue | 1,812 cr | 2,026 cr | 2,206 cr |
| Total income | 1,823 cr | 2,035 cr | 2,219 cr |
| Expenses | 1,462 cr | 1,554 cr | 1,628 cr |
| Profit before tax | 361 cr | 481 cr | 592 cr |
| Tax | 79 cr | 119 cr | 155 cr |
| Net profit (owners' share) | 279 cr | 368 cr | 441 cr |
| Net margin (owners' share, on revenue) | 15.4% | 18.1% | 20.0% |
| EPS (₹) | 5.17 | 6.81 | 8.17 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,770 | ₹4.25 L cr | 53.3 | 8.9% | 12.3% | — |
| Divi's Laboratories Limited | ₹10,064 | ₹2.67 L cr | 74.1 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,650 | ₹1.77 L cr | 82.7 | 11.6% | 10.7% | — |
| Laurus Labs Limitedthis company | ₹2,323 | ₹1.26 L cr | 71.1 | 29.1% | 20.0% | — |
| Zydus Lifesciences Limited | ₹1,241 | ₹1.24 L cr | 33.2 | 13.9% | 11.7% | — |
| Dr. Reddy's Laboratories Limited | ₹1,368 | ₹1.14 L cr | 30.8 | 9.5% | 10.6% | — |
| Cipla Limited | ₹1,397 | ₹1.13 L cr | 32.2 | 9.9% | 11.9% | — |
| Mankind Pharma Limited | ₹2,475 | ₹1.02 L cr | 35.9 | 16.2% | 16.4% | — |
| Aurobindo Pharma Limited | ₹1,695 | ₹97,502 cr | 23.7 | 10.9% | 11.3% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹1.2 / share | 8 May 2026 |
| Dividend | ₹0.8 / share | 31 Oct 2025 |
| Dividend | ₹0.8 / share | 9 May 2025 |
| Dividend | ₹0.4 / share | 6 Nov 2024 |
| Dividend | ₹0.4 / share | 8 May 2024 |
| Dividend | ₹0.4 / share | 2 Nov 2023 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 16 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.